IL232890A0 - Immunogenic therapy for cancer - Google Patents

Immunogenic therapy for cancer

Info

Publication number
IL232890A0
IL232890A0 IL232890A IL23289014A IL232890A0 IL 232890 A0 IL232890 A0 IL 232890A0 IL 232890 A IL232890 A IL 232890A IL 23289014 A IL23289014 A IL 23289014A IL 232890 A0 IL232890 A0 IL 232890A0
Authority
IL
Israel
Prior art keywords
cancer
immunogenic treatment
immunogenic
treatment
Prior art date
Application number
IL232890A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immodulon Therapeutics Ltd
Akle Charles
Mudan Satvinder
Grange John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd, Akle Charles, Mudan Satvinder, Grange John filed Critical Immodulon Therapeutics Ltd
Publication of IL232890A0 publication Critical patent/IL232890A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL232890A 2011-12-02 2014-05-29 Immunogenic therapy for cancer IL232890A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
IL232890A0 true IL232890A0 (en) 2014-07-31

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232890A IL232890A0 (en) 2011-12-02 2014-05-29 Immunogenic therapy for cancer

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2015085162A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
EP3043863B1 (en) 2013-09-11 2019-12-04 The Board of Trustees of the Leland Stanford Junior University Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
RU2733033C2 (ru) * 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
US20220088231A1 (en) 2018-12-03 2022-03-24 Fusion Pharmaceuticals Inc. Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
EP3918069A1 (en) * 2019-01-31 2021-12-08 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
EP1937303A4 (en) 2005-10-21 2009-11-18 Med College Georgia Res Inst INTRODUCTION OF AN INDOLEAMINE-2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND APPLICATIONS THEREOF
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
EP2010216A4 (en) * 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
EP2683386B1 (en) * 2011-03-09 2017-07-05 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
WO2020002905A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
CA2857429A1 (en) 2013-06-06
WO2013079980A1 (en) 2013-06-06
GB201120779D0 (en) 2012-01-11
JP6085611B2 (ja) 2017-02-22
IN2014MN00955A (enExample) 2015-04-24
AU2012343536A1 (en) 2014-06-05
US20190224294A1 (en) 2019-07-25
AU2012343536B2 (en) 2017-08-24
NZ624994A (en) 2016-10-28
SG11201402396XA (en) 2014-10-30
EP2785361A1 (en) 2014-10-08
KR20140097419A (ko) 2014-08-06
CN104023733A (zh) 2014-09-03
BR112014012880A2 (pt) 2017-06-13
MX2014006511A (es) 2014-12-05
US11554166B2 (en) 2023-01-17
US20200338181A1 (en) 2020-10-29
US11318193B2 (en) 2022-05-03
RU2014121335A (ru) 2016-01-27
EP2785361B1 (en) 2018-11-28
JP2014533743A (ja) 2014-12-15
US20140356397A1 (en) 2014-12-04
US20230149525A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
IL232890A0 (en) Immunogenic therapy for cancer
IL232530A0 (en) Combined cancer treatment
PH12014500248A1 (en) Treatment of breast cancer
SG10201508495VA (en) Combination treatment of cancer
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
ZA201307036B (en) Treatment of solid tumours
IL228430A0 (en) Cancer treatment
EP2903644A4 (en) TREATMENT OF CANCER
PL2892535T3 (pl) Sposób leczenia adjuwantowego raka
GB201217892D0 (en) Treatment of cancer
IL275636A (en) Medical combination for cancer treatment
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
AU2012905667A0 (en) Vaccines for treatment of cancer
GB201208296D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
IL232266A0 (en) Cancer treatment methods
GB201017356D0 (en) Combination treatment of cancer